Sugi Predict

Sugi Predict / Compounds / SCHEMBL2425695

SCHEMBL2425695

SCHEMBL2425695

CC(C)Nc1ccc(B2OC(C)(C)C(C)(C)O2)cn1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ HCAR3 P49019 1/20 0.44
▸ DGAT1 O75907 2/20 0.43
▸ LPL P06858 12/20 0.41
▸ LIPG Q9Y5X9 12/20 0.41
▸ CA1 P00915 2/20 0.39
▸ CA2 P00918 2/20 0.39
▸ CA9 Q16790 2/20 0.39
▸ CA12 O43570 1/20 0.39
▸ CA3 P07451 1/20 0.39
▸ CA4 P22748 1/20 0.39
▸ CA6 P23280 1/20 0.39
▸ CA5A P35218 1/20 0.39
▸ CA7 P43166 1/20 0.39
▸ CA14 Q9ULX7 1/20 0.39
▸ CA5B Q9Y2D0 1/20 0.39
▸ TRPM8 Q7Z2W7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL182754 0.81 DGAT1 (0.46) HCAR3DGAT1LPLLIPGCA1
SCHEMBL30059627 0.81 DGAT1 (0.46) HCAR3DGAT1LPLLIPGCA1
SCHEMBL2180601 0.80 HCAR3 (0.48) HCAR3DGAT1LPLLIPGCA1
SCHEMBL16006727 0.80 DGAT1 (0.48) DGAT1LPLLIPGCA1CA2
SCHEMBL16076006 0.80 FFAR1 (0.38) DGAT1LPLLIPGCA1CA2
SCHEMBL13100135 0.80 HCAR3 (0.38) HCAR3
SCHEMBL18436775 0.78 DGAT1 (0.44) HCAR3DGAT1LPLLIPGCA1
SCHEMBL2432651 0.77 LPL (0.50) HCAR3DGAT1LPLLIPGCA1
SCHEMBL31664639 0.77 LPL (0.43) DGAT1LPLLIPGCA1CA2
SCHEMBL20552177 0.77 LPL (0.43) DGAT1LPLLIPGCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240293381-A1 Therapeutic Compounds CELGENE QUANTICEL RES INC (US) 2024-09-05 — — US disclosed
US-11890275-B2 Therapeutic compounds CELGENE QUANTICEL RESEARCH, INC. 2024-02-06 — — US disclosed
US-20210205284-A1 THERAPEUTIC COMPOUNDS CELGENE QUANTICEL RESEARCH, INC. (US) 2021-07-08 — — US disclosed
US-20210205284-A1 THERAPEUTIC COMPOUNDS CELGENE QUANTICEL RESEARCH, INC. (US) 2021-07-08 — — US disclosed
US-11020380-B2 Therapeutic compounds CELGENE QUANTICEL RESEARCH, INC. (US) 2021-06-01 — — US disclosed
US-11020380-B2 Therapeutic compounds CELGENE QUANTICEL RESEARCH, INC. (US) 2021-06-01 — — US disclosed
US-20200163946-A1 THERAPEUTIC COMPOUNDS CELGENE QUANTICEL RESEARCH, INC. (US) 2020-05-28 — — US disclosed
US-20200163946-A1 THERAPEUTIC COMPOUNDS CELGENE QUANTICEL RESEARCH, INC. (US) 2020-05-28 — — US disclosed
US-10617680-B2 Therapeutic compounds CELGENE QUANTICEL RESEARCH, INC. (US) 2020-04-14 — — US disclosed
US-10617680-B2 Therapeutic compounds CELGENE QUANTICEL RESEARCH, INC. (US) 2020-04-14 — — US disclosed
US-20180296543-A1 THERAPEUTIC COMPOUNDS CELGENE QUANTICEL RESEARCH, INC. 2018-10-18 — — US disclosed
EP-2366699-B1 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORP (JP) 2013-08-07 — — EP disclosed
US-8299055-B2 8-substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2012-10-30 — — US disclosed
US-8299055-B2 8-substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2012-10-30 — — US disclosed
EP-2366699-A1 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2011-09-21 — — EP disclosed
EP-2366699-A1 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2011-09-21 — — EP disclosed
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2010-10-14 — — US disclosed
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2010-10-14 — — US disclosed
WO-2010038465-A1 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF 旭化成ファーマ株式会社 (JP) 2010-04-08 — — WO disclosed
WO-2010038465-A1 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF 旭化成ファーマ株式会社 (JP) 2010-04-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11020380-B2 Therapeutic compounds EP300, BRD4, BRD3 HCAR3 2090/4885DGAT1 1333/4885LPL 2458/4885
US-20240293381-A1 Therapeutic Compounds EP300, BRD4, BRD3 HCAR3 2090/4885DGAT1 1333/4885LPL 2458/4885
US-20200163946-A1 THERAPEUTIC COMPOUNDS EP300, BRD4, BRD3 HCAR3 2090/4885DGAT1 1333/4885LPL 2458/4885
US-20180296543-A1 THERAPEUTIC COMPOUNDS EP300, BRD4, BRD3 HCAR3 2090/4885DGAT1 1333/4885LPL 2458/4885
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof RELA, NFKBIA, NFKB2 HCAR3 2306/4885DGAT1 2713/4885LPL 3942/4885
US-20210205284-A1 THERAPEUTIC COMPOUNDS EP300, BRD4, BRD3 HCAR3 2090/4885DGAT1 1333/4885LPL 2458/4885
US-10617680-B2 Therapeutic compounds EP300, BRD4, BRD3 HCAR3 2090/4885DGAT1 1333/4885LPL 2458/4885
US-11890275-B2 Therapeutic compounds EP300, BRD4, BRD3 HCAR3 2090/4885DGAT1 1333/4885LPL 2458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.